Skip to main content

Advertisement

SpringerLink
Log in

Periocular methotrexate versus periocular triamcinolone injections for active thyroid-associated orbitopathy: a randomized clinical trial

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the efficacy and safety of periocular injections of methotrexate versus triamcinolone in the management of active thyroid-associated orbitopathy.

Study design

Prospective, double-masked, randomized clinical trial.

Methods

Participants with bilateral active, moderate-to-severe thyroid-associated orbitopathy were randomly assigned to receive three periocular injections of 7.5 mg methotrexate in one orbit and three periocular injections of 20 mg triamcinolone in the contralateral orbit.

Results

Among the enrolled 25 patients, 18 patients completed the study. A statistically significant reduction of the mean clinical activity score was detected in both arms (from 5.2 ± 0.89 at baseline to 0.9 ± 1.7 at study endpoint, p-value < 0.001 in the methotrexate arm, and from 5.1 ± 0.9 at baseline to 1 ± 1.7 at study endpoint, p-value < 0.001 in the triamcinolone arm), mean proptosis also decreased in both arms (from 25.2 ± 3.4 mm at baseline to 23.8 ± 3.7 mm at study endpoint, p-value = 0.01 in the methotrexate arm, and from 24.2 ± 3.06 mm at baseline to 23.2 ± 3.3 mm at study endpoint, p-value = 0.049 in the triamcinolone arm).

Lid aperture and soft tissue signs improved significantly in both arms in comparison to baseline. A statistically significant reduction in the intraocular pressure was observed in the methotrexate arm but not in the triamcinolone arm. 88.9% of patients in both arms were overall responders at 6 months. There was no significant difference in mean CAS, proptosis, lid aperture or rate of responders between the two arms at any visit. Both drugs were found to be safe with minimal local and systemic complications.

Conclusion

Periocular injections of methotrexate represent an effective and safe alternative option for the management of active, moderate-to-severe thyroid-associated orbitopathy. Although no serious complications occurred during the 6-month follow-up, the possibility of late complications such as orbital fat atrophy cannot be ruled out.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Taylor PN, Zhang L, Lee RW, Muller I, Ezra DG, Dayan CM, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16:104–16.

    Article  CAS  PubMed  Google Scholar 

  3. Genere N, Stan MN. Current and emerging treatment strategies for Graves’ orbitopathy. Drugs. 2019;79:109–24.

    Article  CAS  PubMed  Google Scholar 

  4. Bagheri A, Abbaszadeh M, Yazdani S. Intraorbital steroid injection for active thyroid ophthalmopathy. J Ophthalmic Vis Res. 2020;15:69–79.

    PubMed  PubMed Central  Google Scholar 

  5. Bordaberry M, Marques DL, Pereira-Lima JC, Marcon IM, Schmid H. Repeated peribulbar injections of triamcinolone acetonide: a successful and safe treatment for moderate to severe Graves’ ophthalmopathy. Acta Ophthalmol. 2009;87:58–64.

    Article  CAS  PubMed  Google Scholar 

  6. Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, Martinez H, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88:1380–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Poonyathalang A, Preechawat P, Charoenkul W, Tangtrakul P. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy. J Med Assoc Thai. 2005;88:345–9.

    PubMed  Google Scholar 

  8. Alkawas AA, Hussein AM, Shahien EA. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clin Exp Ophthalmol. 2010;38:692–7.

    Article  PubMed  Google Scholar 

  9. Rivera-Grana E, Lin P, Suhler EB, Rosenbaum JT. Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol. 2015;6:422.

    PubMed  PubMed Central  Google Scholar 

  10. Strianese D, Iuliano A, Ferrara M, Comune C, Baronissi I, Napolitano P, et al. Methotrexate for the treatment of thyroid eye disease. J Ophthalmol. 2014;2014: 128903.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Yong K-L, Chng C-L, Sie NM, Lang S, Yang M, Looi A, et al. Methotrexate as an adjuvant in severe thyroid eye disease: does it really work as a steroid-sparing agent? Ophthalmic Plast Reconstr Surg. 2019;35:369–73.

    Article  PubMed  Google Scholar 

  12. Rubinov A, Zommer H, Aghazadeh H, Weis E. Role of methotrexate in thyroid-related orbitopathy. Can J Ophthalmol. 2018;53:34–8.

    Article  PubMed  Google Scholar 

  13. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf). 2001;55:283–303.

    Article  CAS  PubMed  Google Scholar 

  14. Wiersinga W, Perros P, Kahaly G, Mourits M, Baldeschi L, Boboridis K, et al. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155:387–9.

    Article  CAS  PubMed  Google Scholar 

  15. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10:1519–30.

    Article  CAS  PubMed  Google Scholar 

  16. Bartalena L, Tanda ML, Medea A, Marcocci C, Pinchera A. Novel approaches to the management of graves’ ophthalmopathy. Hormones (Athens). 2002;1:76–90.

    Article  PubMed  Google Scholar 

  17. Khalil HEDM, El Gendy HA, Youssef HAR, Haroun HE, Gheita TA, Bakir HM. The effectiveness of intraocular methotrexate in the treatment of posterior uveitis in Behçet’s disease patients compared to retrobulbar steroids injection. J Ophthalmol. 2016;2016: 1678495.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Benner JD, Dao D, Butler JW, Hamill KI. Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy. BMJ Open Ophthalmol. 2019;4: e000293.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709–16.

    Article  PubMed  Google Scholar 

  20. Mittal J, Mahajan B. Intramatricial injections for nail psoriasis: an open-label comparative study of triamcinolone, methotrexate, and cyclosporine. Indian J Dermatol Venereol Leprol. 2018;84:419–23.

    Article  PubMed  Google Scholar 

  21. Ustuner P, Balevi A, Ozdemir M. The comparison of the efficacy and safety of intralesional triamcinolone acetonide and methotrexate injections for the treatment of fingernail psoriasis. J Ankara Univ Fac Med. 2018;71:145–51.

    Article  Google Scholar 

  22. Carriere C, Baier S, Campana LG, Puviani M, Eisendle K. Palliative intralesional tumescent methotrexate for recurrent locally advanced periocular cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges. 2020;18:1063–6.

    PubMed  Google Scholar 

  23. Searle T, Ali FR, Al-Niaimi F. Intralesional methotrexate in dermatology: diverse indications and practical considerations. Dermatol Ther. 2021;34: e14404.

    Article  CAS  PubMed  Google Scholar 

  24. Lee SJ, Rim THT, Jang SY, Kim CY, Shin DY, Lee EJ, et al. Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections. Graefes Arch Clin Exp Ophthalmol. 2013;251:261–70.

    Article  CAS  PubMed  Google Scholar 

  25. Xu D, Liu Y, Xu H, Li H. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Can J Ophthalmol. 2012;47:34–41.

    Article  CAS  PubMed  Google Scholar 

  26. Yakopson V, Carrasco J, Sharma P, Rabinowitz M, Stefanyszyn M. Effect of intraorbital steroid injections on intraocular pressure in thyroid eye disease. J Thyroid Disord Ther. 2015;4:173.

    Google Scholar 

  27. Chee E, Chee S. Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series. Eye. 2008;22:311–5.

    Article  CAS  PubMed  Google Scholar 

  28. Wang Y, Du B, Yang M, Zhu Y, He W. Peribulbar injection of glucocorticoids for thyroid-associated ophthalmopathy and factors affecting therapeutic effectiveness: a retrospective cohort study of 386 cases. Exp Ther Med. 2020;20:2031–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47:66–80.

    Article  CAS  PubMed  Google Scholar 

  30. Modjtahedi SP, Modjtahedi BS, Mansury AM, Selva D, Douglas RS, Goldberg RA, et al. Pharmacological treatments for thyroid eye disease. Drugs. 2006;66:1685–700.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophthalmology Department, Faculty of Medicine, Cairo University, Al-Saray Street, El-Manial, Cairo, Egypt

    Islam Y. Swaify, Haytham E. Nasr, Rania A. El Essawy & Kareem B. Elessawy

Authors
  1. Islam Y. Swaify
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haytham E. Nasr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rania A. El Essawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kareem B. Elessawy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Islam Y. Swaify.

Ethics declarations

Conflicts of interest

I. Y. Swaify, None; H. E. Nasr, None; R. A. El Essawy, None; K. B. Elessawy, None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding Author: Islam Y. Swaify

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Swaify, I.Y., Nasr, H.E., El Essawy, R.A. et al. Periocular methotrexate versus periocular triamcinolone injections for active thyroid-associated orbitopathy: a randomized clinical trial. Jpn J Ophthalmol 67, 699–710 (2023). https://doi.org/10.1007/s10384-023-01016-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-023-01016-4

Keywords

Search

Navigation